Tarn Cancer Registry (Certified Registry 2020-2025) FRESH-PEF172-en Pascale GROSCLAUDE Tarn Cancer Registry (Certified Registry 2020-2025) RCT FRESH-PEF172-en 172 FRESH-PEF172 Laetitia DAUBISSE-MARLIAC Pascale GROSCLAUDE Registre des cancers du Tarn INSTITUT CLAUDIUS REGAUD Epidemiology France Portal (PEF) DEPARTEMENT DU TARN INSTITUT NATIONAL DU CANCER (INCA) LIGUE NATIONALE CONTRE LE CANCER (LNCC) SANTE PUBLIQUE FRANCE null Laetitia;DAUBISSE-MARLIAC Pascale;GROSCLAUDE ;Registre des cancers du Tarn Francim cancer epidemiology Oncology Neoplasms In the area of public health: (1) To produce quality data to calculate health indicators for incidence, survival and prevalence. (2) To participate in the French network of cancer registries (FRANCIM) and to collaborate with SPF and INCa as part of the national cancer surveillance programme. (3) To work with local stakeholders at a regional level (ARS, Regional cancer network, screening sites) and to concentrate on the local use of the generated knowledge (SROS cancer research, assessment of requirements, initial and continuous training). (4) To assess the impact of the disease on the population scale: prevalence, survival with or without the disease. In the area of research: (1) To learn about the distribution of therapeutic innovations throughout the population and its impact from a health and economic standpoint (2) To assess the heterogeneity factors in the distribution of cancer treatment developments and their impact in terms of social health inequality in primary and secondary healthcare usage. (3) To participate in studies initiated by others by providing them with local knowledge from the registry team and data collected in Tarn. null France Occitanie Individuals Patients population Male Female Infant, Newborn (birth to 28 days) Infant (28 days to 2 years) Child, Preschool (2 to 5 years) Child (6 to 12 years) Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) All cases of invasive malignant tumors (except basocellular skin carcinoma) + in situ breast, colorectal, cervical, urinary tract and borderline ovarian tumours. Clinical data Biological data Socio-demographic data Paraclinical data (non-biological) : Other CIM-O; TNM FRANCIM procedure and ENCR rules Health event/morbidity Health care consumption and services Other >= 20000 individuals Converting or copying information into a structured record Observational Study Observational Study Morbidity registry 60,000 Unknown Restricted access Access on specific project only